Back to top
more

Agios Pharmaceuticals (AGIO)

(Delayed Data from NSDQ)

$33.09 USD

33.09
577,552

-0.54 (-1.61%)

Updated Aug 21, 2026 04:00 PM ET

After-Market: $33.13 +0.04 (0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (151 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label

by Zacks Equity Research

Agios Pharmaceuticals wins FDA approval for Aqvesme in alpha- and beta-thalassemia, making mitapivat the only approved option, despite a new REMS.

Zacks Equity Research

Agios Awaits Pyrukynd Decision in Thalassemia as FDA Misses Due Date

by Zacks Equity Research

AGIO faces uncertainty as the FDA misses its Dec. 7 deadline related to the sNDA for Pyrukynd in thalassemia and offers no new timeline.

Zacks Equity Research

AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results

by Zacks Equity Research

Agios slides to a 52-week low after mixed phase III RISE UP data show a hemoglobin boost but no significant cut in pain crises.

Zacks Equity Research

AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues

by Zacks Equity Research

Agios posts a narrower-than-expected third-quarter loss as Pyrukynd drives a 44% revenue rise, with potential label expansions on the horizon.

Zacks Equity Research

Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of +7.77% and +27.69%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia

by Zacks Equity Research

Agios shares tank as the FDA extends the review period for Pyrukynd in thalassemia by three months, pushing the final ruling to Dec. 7, 2025.

Zacks Equity Research

Why Is Vertex (VRTX) Up 6.9% Since Last Earnings Report?

by Zacks Equity Research

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -10.92% and +34.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.